Innate Pharma Cash Flow Statement (2019-2025) | IPHA

Cash Flow Statement Jun2019 Dec2019 Jun2020 Dec2020 Jun2021 Dec2021 Jun2022 Dec2022 Jun2023 Dec2023 Jun2024 Dec2024 Jun2025
Operating Activities
Net Income -17.47M-4.31M-75.30M7.53M-8.39M-0.08M-133.650.62M-6.17M-26.11M-48.62M-25.61M
Gains from Investment Securities -1.14M
Asset Writedowns and Impairment -51.90M-0.04M
Change in Working Capital 44.55M-63.44M-58.67M-15.22M-11.31M-11.71M-12.76M-20.18M-34.53M-72.43M41.85M
Cash from Operations -63.91M-61.72M-37.53M-66.87M-19.54M-12.48M-35.03M-7.37M
Investing Activities
Capital Expenditures -0.83M-1.41M-0.60M-1.08M-0.29M-1.06M-0.45M-0.55M-0.34M-0.38M-0.42M
Sales of Property, Plant and Equipment -0.01M0.01M-0.00M
Change in Intangibles -72.06M-70.98M-10.25M-12.37M-0.04M-0.46M-0.60M-2.15M
Cash from Investing Activities -69.44M-68.76M-13.34M-15.94M-0.30M-1.05M-0.42M-0.27M
Financing Activities
Debt Issuance and Repayment
Long-Term Debt Repayments -0.82M-2.19M-1.13M-2.68M-1.36M-2.37M-1.02M-2.07M-1.74M-2.54M-9.55M
Misc.
Cash from Financing Activities -0.87M-1.32M-1.40M-1.48M-1.02M-1.87M-1.36M-2.12M-6.42M
Exchange Rate Effect -0.00M-0.01M-0.21M-0.55M-0.71M-0.44M-0.54M
Change in Cash -3.30M-78.58M-78.81M-39.51M-37.79M-0.86M-19.93M-13.95M-14.65M-0.00M-4.50M
Free Cash Flow 0.83M1.41M-63.31M-60.64M-37.24M-65.81M0.45M-19.00M-12.15M-34.65M-6.95M
Net Cash Flow -70.31M-68.76M-78.57M-79.07M-39.30M-67.92M-1.45M-21.41M-14.11M-37.15M-13.79M